Search

Displaying results 9981 - 9990 of 10000 in total
  1. Drug

    Feladilimab

    go.drugbank.com/drugs/DB16415
    Investigational

    Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell

  2. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030, A241040] Mannan-associated lectin-binding serine protease-2 (MASP-2) is a major effector in the complement lectin pathway. … [A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy

    Synonyms: (1-445) (HOMO SAPIENS VH (IGHV2-26*01 (94%) (IGHD)-I, MASP-2 antibody
  3. Drug

    Allocetra

    go.drugbank.com/drugs/DB16424
    Investigational

    Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune … these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals so that the immune system is rebalanced back to normal -- averting a

  4. Drug

    Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

    go.drugbank.com/drugs/DB16431
    Experimental

    Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated … to the hepatitis B surface antigen[A226593].

    Synonyms: RBD SARS-CoV-2 HBsAg VLP vaccine
  5. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein[L30453]. … MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines

  6. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  7. Drug

    V591

    go.drugbank.com/drugs/DB16438
    Investigational

    The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery[L30593]. … Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593].

  8. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613]. … EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608].

  9. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.

  10. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

    Categories: Heterocyclic Compounds, 1-Ring